Sign In
Buy LPCN
$2.12
+0.0100 (+0.474%)
At Close: Jul 31, 2026
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
08:00am, Wednesday, 18'th Feb 2026
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
08:00am, Tuesday, 20'th Jan 2026
SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
2026 Asset Growth: Why Federal Compliance Is the New Metric
12:20pm, Monday, 19'th Jan 2026
VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting t
Company on track to report topline results early in the second quarter of 2026 Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL)
02:18am, Friday, 26'th Dec 2025
Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two busi
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
08:00am, Tuesday, 16'th Dec 2025
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026 Topline results on track for the second quarter of 2026 SALT LAKE CITY , Dec. 16, 2025 /PRNewswire/ -- Lipocine I
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
08:00am, Tuesday, 18'th Nov 2025
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned More than half of planned participants have completed dosing with no dose
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
10:10am, Thursday, 06'th Nov 2025
Lipocine (LPCN) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.44 per share a year ago.
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
08:00am, Thursday, 06'th Nov 2025
SALT LAKE CITY , Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral de
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
08:00am, Tuesday, 04'th Nov 2025
SALT LAKE CITY , Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
08:00am, Tuesday, 30'th Sep 2025
One-Third of Patients Randomized; Topline Results Expected in 2Q 2026 DSMB Safety Review Update Planned for 4Q 2025 SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biop
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
04:30pm, Friday, 05'th Sep 2025
SALT LAKE CITY , Sept. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective or
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
08:00am, Tuesday, 26'th Aug 2025
SALT LAKE CITY , Aug. 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective or
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
08:00am, Tuesday, 05'th Aug 2025
SALT LAKE CITY , Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
08:00am, Thursday, 26'th Jun 2025
Phase 3 Top Line Results Expected Q2 2026 SALT LAKE CITY , June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to dev
